London-based Sava Technologies raised $36 million in Series B from Ascensia Diabetes Care to commercialize its subcutaneous glucose sensor. A European launch is scheduled for 18 to 24 months after obtaining CE approval.
London-based Sava Technologies raised $36 million in Series B from Ascensia Diabetes Care to commercialize its subcutaneous glucose sensor. A European launch is scheduled for 18 to 24 months after obtaining CE approval.